To compare real-world outcomes related to treatment effectiveness of vedolizumab versus infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) using 4 different statistical approaches to account for potential unbalanced confounding factors
Latest Information Update: 22 May 2019
At a glance
- Drugs Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
Most Recent Events
- 22 May 2019 Results presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 22 May 2019 New trial record